STOCK TITAN

Mainz Biomed N.V. - MYNZ STOCK NEWS

Welcome to our dedicated news page for Mainz Biomed N.V. (Ticker: MYNZ), a resource for investors and traders seeking the latest updates and insights on Mainz Biomed N.V..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mainz Biomed N.V.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mainz Biomed N.V.'s position in the market.

Rhea-AI Summary
Mainz Biomed announces positive results from its ColoFuture study, with sensitivity for colorectal cancer of 94% and sensitivity for advanced adenoma of 81%. The company eagerly awaits results from its eAArly DETECT clinical trial. The portfolio of mRNA biomarkers acquired from Université de Sherbrooke enhances ColoAlert®'s technical profile to increase diagnostic rates for CRC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.85%
Tags
-
Rhea-AI Summary
Mainz Biomed announces strategic partnership with Ärztliches Labor Dr. Buhlmann to strengthen its position in the German market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.21%
Tags
partnership
-
Rhea-AI Summary
Mainz Biomed anticipates read outs of clinical data from EU and US feasibility studies in September and Q4. CEO to present at H.C. Wainwright Global Investment Conference. mRNA biomarkers evaluated for colorectal cancer and advanced adenoma detection. Potential to revolutionize CRC diagnosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.54%
Tags
conferences
Rhea-AI Summary
Mainz Biomed announces commercial launch of ColoAlert® in Poland through strategic collaboration with testDNA. Partnership aims to improve access to screening tools for early colorectal cancer detection. Poland ranks 7th in the world for highest mortality rate. Low national participation in CRC screening highlights need for alternative options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.78%
Tags
none
-
Rhea-AI Summary
Mainz Biomed N.V. (NASDAQ:MYNZ) Announces 108% Increase in ColoAlert® Revenue and Positive Progress in Clinical Trials in Q2 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.22%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.95%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.56%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.08%
Tags
partnership
Mainz Biomed N.V.

Nasdaq:MYNZ

MYNZ Rankings

MYNZ Stock Data

21.23M
16.84M
16.59%
1.06%
1.51%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Germany
Mainz

About MYNZ

mainz biomed is aiming to become a leading provider of easy-to-use diagnostic solutions for patients everywhere. we develop innovative products that quickly and easily identify the early onset of several leading deadly conditions including colorectal and pancreatic cancers. visit our website www.mainzbiomed.com to learn more about our company and our mission to save lives through science.